EP4157885A4 - ANTI-CLDN18.2 ANTIBODIES AND THEIR DIAGNOSTIC USES - Google Patents

ANTI-CLDN18.2 ANTIBODIES AND THEIR DIAGNOSTIC USES

Info

Publication number
EP4157885A4
EP4157885A4 EP21812540.9A EP21812540A EP4157885A4 EP 4157885 A4 EP4157885 A4 EP 4157885A4 EP 21812540 A EP21812540 A EP 21812540A EP 4157885 A4 EP4157885 A4 EP 4157885A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
diagnostic uses
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21812540.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4157885A1 (en
Inventor
Xueming Qian
Xinlai Yao
Huanhuan Guo
Hongjun Li
Yi Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Transcenta Therapeutics Co Ltd
Original Assignee
Suzhou Transcenta Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Transcenta Therapeutics Co Ltd filed Critical Suzhou Transcenta Therapeutics Co Ltd
Publication of EP4157885A1 publication Critical patent/EP4157885A1/en
Publication of EP4157885A4 publication Critical patent/EP4157885A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
EP21812540.9A 2020-05-25 2021-05-24 ANTI-CLDN18.2 ANTIBODIES AND THEIR DIAGNOSTIC USES Pending EP4157885A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020092092 2020-05-25
PCT/CN2021/095411 WO2021238831A1 (en) 2020-05-25 2021-05-24 Anti-cldn18.2 antibodies and diagnostic uses thereof

Publications (2)

Publication Number Publication Date
EP4157885A1 EP4157885A1 (en) 2023-04-05
EP4157885A4 true EP4157885A4 (en) 2024-07-10

Family

ID=78745623

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21812540.9A Pending EP4157885A4 (en) 2020-05-25 2021-05-24 ANTI-CLDN18.2 ANTIBODIES AND THEIR DIAGNOSTIC USES

Country Status (10)

Country Link
US (1) US20230331836A1 (zh)
EP (1) EP4157885A4 (zh)
JP (1) JP2023527937A (zh)
KR (1) KR20230016212A (zh)
CN (1) CN115836090A (zh)
AU (1) AU2021279777A1 (zh)
CA (1) CA3184008A1 (zh)
MX (1) MX2022014896A (zh)
TW (1) TW202212360A (zh)
WO (1) WO2021238831A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240269315A1 (en) 2021-06-02 2024-08-15 Bio-Thera Solutions, Ltd. Drug conjugate and use thereof
CN114539410B (zh) * 2022-03-15 2023-09-05 苏州量化细胞生物科技有限公司 Cldn18.2结合抗体、探针及在cldn18.2表达细胞的单细胞测序中的应用
WO2023196882A1 (en) * 2022-04-06 2023-10-12 Zai Lab (Us) Llc Claudin 18.2 immunohistochemistry assay and use thereof
CN114428174B (zh) * 2022-04-07 2022-07-08 北京肿瘤医院(北京大学肿瘤医院) 一种胃癌预后生物标志物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2019174617A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
WO2019219089A1 (en) * 2018-05-18 2019-11-21 Bridge Health Bio-Tech Co., Ltd Anti-claudin 18.2 antibodies and uses thereof
WO2020082209A1 (zh) * 2018-10-22 2020-04-30 上海吉倍生物技术有限公司 抗cldn18.2抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2015113576A1 (en) * 2014-01-29 2015-08-06 Biontech Ag Peptide mimotopes of claudin 18.2 and uses thereof
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2019174617A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
WO2019219089A1 (en) * 2018-05-18 2019-11-21 Bridge Health Bio-Tech Co., Ltd Anti-claudin 18.2 antibodies and uses thereof
WO2020082209A1 (zh) * 2018-10-22 2020-04-30 上海吉倍生物技术有限公司 抗cldn18.2抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, no. 6, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP002986051, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
See also references of WO2021238831A1 *

Also Published As

Publication number Publication date
EP4157885A1 (en) 2023-04-05
MX2022014896A (es) 2023-01-04
CA3184008A1 (en) 2021-12-02
WO2021238831A1 (en) 2021-12-02
KR20230016212A (ko) 2023-02-01
JP2023527937A (ja) 2023-06-30
TW202212360A (zh) 2022-04-01
CN115836090A (zh) 2023-03-21
US20230331836A1 (en) 2023-10-19
AU2021279777A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG10202111141WA (en) Anti-claudin 18.2 antibodies and uses thereof
EP3878863A4 (en) ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
ZA202106880B (en) Anti-claudin 18.2 antibody and application thereof
EP4157885A4 (en) ANTI-CLDN18.2 ANTIBODIES AND THEIR DIAGNOSTIC USES
IL280467A (en) Antibody constructs for CLDN18.2 and CD3
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
EP3992209A4 (en) CLDN18.2 ANTIBODY AND ITS USE
IL291299A (en) Anti-TNFR2 antibodies, preparations containing them and their uses
WO2008122551A3 (en) Anti-epcam antibody and uses thereof
IL283379A (en) Bispecific antibodies anti-claudin 18.2 and anti-4-1 bb and their uses
GB202017058D0 (en) Antibodies and uses thereof
SG11202108281UA (en) Claudin 6 antibodies and uses thereof
EP4105237A4 (en) ANTI-CLDN18.2 ANTIBODIES AND ITS USE
WO2020010079A3 (en) Anti-steap1 antigen-binding protein
IL308382A (en) New anti-CD276 antibodies and their uses
EP4132569A4 (en) ANTI-PHF-TAU ANTIBODIES AND USES
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
IL307267A (en) ANTI-CD122 antibodies and their uses
SG11202011232VA (en) Anti-cd63 antibodies, conjugates, and uses thereof
IL304412A (en) Antibodies against cd112r and uses thereof
EP3847192A4 (en) MONOCLONAL ANTIBODIES ANTI-ENDOTROPHIN AND THEIR USE
WO2019133902A3 (en) Antibodies and assays for ccl14
EP4086287A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USE THEREOF
IL308204A (en) Antibodies against NKG2D and their uses

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240607

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20240604BHEP

Ipc: C07K 16/30 20060101AFI20240604BHEP